<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Cannon, Christopher P.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ezetimibe Plus Statin Reduces CV Events after ACS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">Statins have been demonstrated to reduce morbidity and mortality; however, adding other lipid-modifying therapies to statin treatment has not demonstrated a clear benefit. This article presents data from the Improved Reduction of Outcomes: Vytorin (Ezetimibe/Simvastatin) Efficacy International Trial [IMPROVE-IT; NCT00202878]. The purpose of the IMPROVE-IT trial was to evaluate the clinical benefit of combination therapy with ezetimibe plus simvastatin compared with simvastatin monotherapy in lowering LDL-C levels.</style></abstract><number><style face="normal" font="default" size="100%">52</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>